0.03 | 2.16%
| Price and Volume | |
|---|---|
| Recent Price | 1.42 |
| 52 Week High | 4.50 |
| 52 Week Low | 1.35 |
| Avg. Daily Vol. (Mil) | 0.70 |
| Beta (3 year) | 1.61 |
| Share Related Items | |
| Mkt Cap (Mil) | 187.56 |
| Shares Out (Mil) | 132.09 |
| Float (Mil) | 130.36 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 11.00 |
| Current Ratio | 11.90 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 85.76 |
| Price/Book | 1.43 |
| Price/Cash Flow | -2.20 |
| Per Share Data | |
| Earnings | -0.74 |
| Sales | 0.02 |
| Book Value | 0.99 |
| Cash Flow | -0.65 |
| Business Summary | |
|---|---|
| Geron Corporation is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. | |
| General Information | |
| 230 Constitution Drive
Menlo Park, CA 94025 |
|
| www.geron.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 178 | |
| CEO: Dr. John A. Scarlett,M.D | |
| Short Interest | |
| Current Month (Mil) | 7.38 |
| Previous Month (Mil) | 7.80 |
| Short Interest Ratio (Days) | 12.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -64.60 |
| Return on Investments | -69.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet